New drug aims to halt Alzheimer's decline in Early-Stage patients
NCT ID NCT07612150
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called TML-6 in 210 people with early Alzheimer's disease. Over 52 weeks, researchers will compare those taking TML-6 to those on a placebo to see if the drug can slow or stop memory and thinking problems. The goal is to find a treatment that helps people maintain their daily function longer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple questionnaire empower dementia caregivers after hospital stays?
- Could your heart hold the key to Alzheimer's prevention?
- Can a nudge in your chart unlock Life-Saving genetic clues?
- Can a Voice-Based app map healthy brain aging across 80 years?
- Can MRI reveal the Brain's response to deep brain stimulation?
- Can brain scans and gut bacteria reveal Alzheimer's secrets?